| 6/6/2024 | CV | Market Commentary: Hertz eyes convertible sale; UGI, Granite Construction on deck; Fortuna jumps on debut
|
| 11/15/2023 | CV | Market Commentary: Helix Energy refinances convertibles via junk bonds; Halozyme rises; Spirit Air rebounds
|
| 11/15/2023 | CV | Market Commentary: Morning Commentary: Convertibles secondary gains; Halozyme active; Spirit Air rebounds
|
| 7/25/2023 | CV | Market Commentary: High-grade convertible names dominate; Uber notes better; Halozyme rises; earnings eyed
|
| 7/25/2023 | CV | Market Commentary: Morning Commentary: Granite Construction convertible notes active early; Halozyme rises
|
| 7/17/2023 | CV | Market Commentary: Biopharma names up in convertibles action; EV truck makers woeful as competition rises
|
| 1/11/2023 | CV | Market Commentary: Halozyme convertibles active on missed guidance, notes redemption; Live Nation comes in
|
| 1/11/2023 | CV | Market Commentary: Morning Commentary: Halozyme convertibles in focus on missed guidance, notes redemption
|
| 1/11/2023 | CVLM | Halozyme to redeem all 1.25% convertible notes due 2024 on March 17
|
| 8/18/2022 | CVLM | Halozyme exchanges portion of 1.25% convertible notes due 2024
|
| 8/18/2022 | CV | Halozyme issues $720 million of six-year convertibles after greenshoe exercised in full
|
| 8/16/2022 | CV | Market Commentary: Sunnova upsizes convertible notes; Halozyme jumps on trading debut; FuboTV improves
|
| 8/16/2022 | CV | Market Commentary: Morning Commentary: Sunnova convertibles offering eyed; Halozyme jumps on debut
|
| 8/16/2022 | CV | New Issue: Halozyme prices upsized $625 million six-year convertible notes to yield 1%, up 30%
|
| 8/15/2022 | CV | Market Commentary: Sunnova on deck; Halozyme convertible offering oversubscribed; UpHealth exchanges
|
| 8/15/2022 | CV | Market Commentary: Morning Commentary: Halozyme Therapeutics convertible notes on tap; UpHealth exchanges
|
| 8/15/2022 | CV | Halozyme talks $500 million six-year convertible notes to yield 1%-1.5%, up 27.5%-32.5%
|
| 3/1/2021 | CV | Halozyme greenshoe lifts 0.25% convertibles to $805 million
|
| 2/26/2021 | CV | Market Commentary: Spotify hits aftermarket, contracts on debut; Enphase under pressure; Halozyme active
|
| 2/25/2021 | CV | Market Commentary: Spotify exchangeables eyed; $2.1 billion of notes flood secondary on weak day for stocks
|
| 2/25/2021 | CV | Market Commentary: Morning Commentary: Spotify exchangeables eyed; $2.1 billion of paper floods secondary
|
| 2/25/2021 | CV | New Issue: Halozyme prices upsized $700 million six-year convertibles to yield 0.25%, up 50%
|
| 2/24/2021 | CV | Market Commentary: Spotify, Green Plains, Chefs’ Warehouse on tap; Halozyme, Enphase convertibles eyed
|
| 2/24/2021 | CV | Market Commentary: Morning Commentary: Halozyme, Enphase Energy convertibles eyed; Dropbox up on debut
|
| 2/23/2021 | CV | Market Commentary: Halozyme convertibles on tap; Dropbox eyed, talk tightened; MicroStrategy tanks outright
|
| 2/23/2021 | CV | Halozyme talks $500 million six-year convertible notes to yield 0.25%-0.75%, up 45%-50%
|
| 11/21/2019 | CV | Market Commentary: Overnight Liberty Media/Sirius exchangeables model cheap; Tilray adds with higher shares
|
| 11/18/2019 | CV | Halozyme greenshoe lifts 1.25% five-year convertibles to $460 million
|
| 11/15/2019 | CV | Market Commentary: Sea continues to trade actively after debut; new CyberArk, Halozyme trade some; RH jumps
|
| 11/15/2019 | CV | Market Commentary: Morning Commentary: Sea convertibles continue to trade actively in line with shares
|
| 11/14/2019 | CV | Market Commentary: CyberArk outperforms among new issues; Sea, Halozyme also rise outright and on swap
|
| 11/14/2019 | CV | New Issue: Halozyme sells $400 million 1.25% five-year convertibles, up 35%
|
| 11/13/2019 | CV | Market Commentary: j2 Global edges par in active trade; planned Sea notes look cheap at midpoint of talk
|
| 11/12/2019 | CV | Market Commentary: j2 Global deal edges fair value at midpoint of talk; Halozyme, CyberArk Software on tap
|
| 11/12/2019 | CV | Halozyme plans $400 million offering of five-year convertibles to yield 1%-1.5%, up 35%-40%
|
| 2/9/2012 | CVHYPF | Halozyme files automatic shelf covering stock, debt and preferreds
|
| 1/5/2010 | CVHY | Halozyme files $100 million shelf covering stock, debt and preferreds
|
| 12/1/2008 | CV | Halozyme Therapeutics files $50 million shelf
|
| 6/10/2005 | CV | Halozyme Therapeutics files $50 million shelf
|
